On Friday, June 29, Arie Weinstock, MD, medical director of pediatric neurology at Oishei Children's Hospital was joined by Senator Chris Jacobs, Assemblyman Sean Ryan and a patient family to advocate for the legalization of a cannabidiol drug, Epidiolex, that has proven to significantly decrease the severity and frequency of seizures in pediatric patients during a lengthy clinical trial at Oishei Children's Hospital.
Proven effective in treating seizures with two rare and severe forms of epilepsy, Dravet and Lennox-Gastault syndromes, Epidiolex is a purified form of the drug cannabidiol (CBD). Despite recently becoming the first plant-derived cannabinoid product to be federally approved, the life-changing drug will not be available to New Yorkers if the bill is not signed into law by Governor Cuomo.
According to Dr. Weinstock, "Epidiolex has substantially reduced seizures in patients with two rare forms of epilepsy, and the study we've participated in will help thousands of patients across New York and the United States. We're conducting studies that bring new hope to patients, and the fact that we're able to do them here in Buffalo is a testament to the commitment the University at Buffalo, the Jacobs School of Medicine and Biomedical Sciences at UB and Oishei Children's Hospital have made to leading medical innovations."